Moleculin Biotech Inc (MBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.02M
Last updated: Nov 17, 2026 at 10:59 AM ET
Moleculin Biotech Inc (MBRX) Stock Forecast
Analysts expect Moleculin Biotech (MBRX) to earn -$65.33 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$65.33
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$23.40
- EPS consensus
- Next report
- Mar 16, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$65.33 | -$70.60 to -$58.80 | 3 |
| Dec 31, 2027 | -$23.40 | -$32.20 to -$14.00 | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$8.70 | -$9.21 to -$8.40 | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$92.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$65.33 | -$64.70 | -$108.13 | -$92.00 | -$92.00 | N/A |
| Fiscal year ending Dec 31, 2027 | -$23.40 | -$42.73 | -$76.87 | -$76.87 | -$76.87 | N/A |
Frequently Asked Questions About MBRX
What is the MBRX stock forecast?
Consensus analyst estimates put Moleculin Biotech's EPS at -$65.33 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate MBRX stock?
Of 3 analysts covering Moleculin Biotech, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MBRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$65.33, with estimates from -$70.60 to -$58.80 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$23.40, with estimates from -$32.20 to -$14.00 from 3 analysts.
How many analysts cover MBRX?
3 analysts rate Moleculin Biotech stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MBRX pages: Overview, Earnings, Forecast, Financials, Competitors